论文部分内容阅读
目的:观察促性腺激素释放激素激动药丙氨瑞林联合莉芙敏片治疗子宫内膜异位症,对患者p53、p21、MDM2蛋白表达的影响。方法:子宫内膜异位症患者276例随机分为观察组(149例)和对照组(127例)。观察组患者予丙氨瑞林联合莉芙敏片治疗,对照组患者仅予丙氨瑞林治疗,两组疗程均为8个月。比较两组患者治疗前后p53、p21、MDM2蛋白表达阳性率,观察两组患者临床症状的改善以及药品不良反应。结果:治疗后,两组患者p53、MDM2、p21阳性率较治疗前均明显降低(P<0.05),且观察组患者p53、p21、MDM2蛋白表达阳性率明显低于对照组(P<0.05);对照组患者的症状无改善,并有所加重,差异无统计学意义(P>0.05),但观察组患者痛经、月经异常、性交疼痛等症状均较治疗前明显改善(P<0.05),且明显优于对照组(P<0.05)。观察组总不良反应发生率为35.57%,低于对照组的55.91%(P<0.05)。结论:丙氨瑞林联合莉芙敏片治疗子宫内膜异位症,能够有效地降低患者p52、p21、MDM2的阳性表达率,改善患者症状,减少药品不良反应。
Objective: To observe the effect of grenadlin combined with Livmin on the expression of p53, p21 and MDM2 protein in patients with endometriosis. Methods: 276 patients with endometriosis were randomly divided into observation group (149 cases) and control group (127 cases). Patients in the observation group were treated with Alarelin combined with Livmin tablets, and patients in the control group received only Alarelin treatment. The course of treatment was 8 months in both groups. The positive rates of p53, p21 and MDM2 protein expression in the two groups before and after treatment were compared. The clinical symptoms and side effects of the two drugs were observed. Results: After treatment, the positive rates of p53, MDM2 and p21 in both groups were significantly lower than those before treatment (P <0.05), and the positive rates of p53, p21 and MDM2 in the observation group were significantly lower than those in the control group (P <0.05) (P0.05) .However, the symptoms of dysmenorrhea, menstrual abnormalities and painful intercourse in the observation group were significantly improved compared with those before treatment (P <0.05), while those in the control group were not improved (P> 0.05) And significantly better than the control group (P <0.05). The incidence of adverse reactions in the observation group was 35.57%, lower than 55.91% in the control group (P <0.05). Conclusion: Ariminene combined with Levynipin in the treatment of endometriosis can effectively reduce the positive rate of p52, p21 and MDM2, improve the symptoms of patients and reduce the adverse reactions of drugs.